Luis Tobalina

AstraZeneca (United Kingdom) — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index742citations36works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bioinformatics and Genomic Networks(15), Microbial Metabolic Engineering and Bioproduction(9), Gene Regulatory Network Analysis(8), Computational Drug Discovery Methods(6), PARP inhibition in cancer therapy(6)

Publications36 total

Supplementary Table 1 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
2025Open Access
Data from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
2025Open Access
Supplementary Figure 3 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
2025Open Access
Supplementary Figure 6 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
2025Open Access
Supplementary Figure 1 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
2025Open Access
Supplementary Figure 4 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
2025Open Access
Supplementary Figure 7 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
2025Open Access
Supplementary Figure 2 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
2025Open Access
Supplementary Figure 5 from Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
2025Open Access
Early ctDNA Dynamics Inform First-Line Therapy in Patients with Extensive-Stage Small Cell Lung Cancer
Clinical Cancer Research·2025· 1 citedOpen Access
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Genome Medicine·2024· 51 citedOpen Access
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models
Cancers·2023· 5 citedOpen Access
Proteomic Dynamics of Breast Cancer Cell Lines Identifies Potential Therapeutic Protein Targets
Molecular & Cellular Proteomics·2023· 17 citedOpen Access
BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer.
Journal of Clinical Oncology·2022· 14 cited
Patient-specific Boolean models of signalling networks guide personalised treatments
eLife·2022· 94 citedOpen Access
Author response: Patient-specific Boolean models of signalling networks guide personalised treatments
2022Open Access
Patient-specific Boolean models of signaling networks guide personalized treatments
2021· 4 citedOpen Access
PHONEMeS: Efficient Modeling of Signaling Networks Derived from Large-Scale Mass Spectrometry Data
Journal of Proteome Research·2021· 29 citedOpen Access
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
British Journal of Cancer·2020· 68 citedOpen Access
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance
Annals of Oncology·2020· 170 cited
page 1 of 2Next →

Frequent Co-authors

Julio Sáez-Rodríguez(11), T. Hedley Carr(11), Carmela Ciardullo(10), Philip Szekeres(10), Silvija Kraljevic(10), Lauren A. Byers(10), Giulia Fabbri(10), Francisco J. Planes(7), Jon Pey(7), Pauline Traynard(6), Laurence Calzone(6), Vigneshwari Subramanian(5), Bence Szalai(5), Joshua Armenia(4), Mark J. O’Connor(4), Arnau Montagud(4), Jonas Béal(4), Emmanuel Barillot(4), Alberto Rezola(4), Josep V. Forment(3)